^
Association details:
| Biomarker: | EGFR S492R |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Erbitux (cetuximab) (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer
Excerpt:
A subject with cetuximab resistance harboring the S492R mutation responded to treatment with panitumumab.
DOI:
10.1038/nm.2609
Source:
Title:
Colorectal adenocarcinoma-derived EGFR mutants are oncogenic and sensitive to EGFR-targeted monoclonal antibodies, cetuximab and panitumumab
Published date:
07/19/2019
Excerpt:
Here, through systematic functional screening of 21 recurrent EGFR mutations selected from public data sets, we show that 11 colon cancer-derived EGFR mutants (G63R, E114K, R165Q, R222C, S492R, P596L, K708R, E709K, G719S, G724S and L858R) are oncogenic…these EGFR mutants are inhibited by cetuximab or panitumumab in vivo and in vitro. Taken together, we propose that a subset of EGFR mutations can serve as genomic predictors for response to anti-EGFR antibodies and that metastatic CRC patients with such mutations may benefit from these drugs as part of the first-line therapy.
DOI:
10.1002/ijc.32499
Source:
Title:
The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer
Excerpt:
However, in cetuximab-treated S492R EGFR-mutant DCR7 xenografts, an increase in tumor growth rate was observed after approximately 40 days (Fig. 3B).
DOI:
10.1158/1078-0432.CCR-15-2400
